Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

BACKGROUND: Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first‐line setting remain poorly defined. METHODS: We retrospectively review...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuanquan, Psutka, Sarah P., Parikh, Anish B., Li, Mingjia, Collier, Katharine, Miah, Abdul, Mori, Sherry V., Hinkley, Megan, Tykodi, Scott S., Hall, Evan, Thompson, John A., Yin, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385597/
https://www.ncbi.nlm.nih.gov/pubmed/35304832
http://dx.doi.org/10.1002/cam4.4679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385597/
https://www.ncbi.nlm.nih.gov/pubmed/35304832
http://dx.doi.org/10.1002/cam4.4679

Ejemplares similares